Mayo Clinic, Rochester, MN
Leah C Soderberg , Vanessa Wookey , Jessica L. Mitchell , Jacob A. Jochum , Nguyen H. Tran , Thorvardur Ragnar Halfdanarson , Joleen M. Hubbard , Rondell P. Graham , Kellie Leanne Mathis , Amit Mahipal , Zhaohui Jin
Background: Rectal cancer treatment paradigm has been evolving over time. Historically, for locally advanced rectal cancer, standard therapy (ST) consisted of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Recently, total neoadjuvant treatment (TNT) approach that delivers both neoadjuvant chemotherapy (CAPOX or FOLFOX) and chemoradiation (or radiation only) prior to surgery is increasingly being utilized. The prognostic and predictive values of mismatch repair deficient (dMMR) in rectal cancer is not well characterized. Most dMMR patients receive the same treatment as MMR proficient (pMMR) patients although there is limited data that dMMR rectal cancer patients may not have the same level of benefits from neoadjuvant treatment. This retrospective study aims to evaluate the clinicopathological/molecular characteristics, disease response, and clinical outcomes in dMMR localized rectal cancer patients. Methods: A retrospective analysis was conducted on consecutive adult patients with a diagnosis of dMMR rectal cancer who were treated at Mayo Clinic between January 2000 to September 2021. Patients who presented with concurrent primary non-colorectal malignancies were excluded. The distributions of demographics, clinicopathological features, biomarkers, and outcome data were collected. Survival was assessed using Kaplan-Meier curves and Cox models were stratified by treatment arms to determine significance of treatment strategies. Results: Forty-one patients were identified with a median age of 45.3 years. Thirty (73.2%) pts were male. The most common MMR were loss of MSH2 and MSH6 (12/42; 29.3%) followed by loss of MLH1 and PMS2 (10/42; 24.4%) and solitary loss of MSH2 (4/42; 9.8%). The treatment, pathological response, and clinical outcomes are listed in table. With a median follow up of 101 months, only 6 patients (14.3%) died and median overall survival was not reached. Conclusions: Our findings showed dMMR localized rectal cancer responded to both ST and TNT with good clinical outcomes.
Total Neoadjuvant Therapy | Standard Therapy | No Neoadjuvant Therapy | |
---|---|---|---|
Patients (number) | 8 | 21 | 12 |
Gender (number, %) Male Female | 6 (75%) 2 (25%) | 18 (85.7%) 3 (14.3%) | 7 (58.3%) 5 (41.7%) |
Disease stage change after neoadjuvant treatment: - Down-staged (complete response) - Stable - Progression | 5 (3) 1 2 | 14 (6) 5 2 | N/A |
Number of patients with recurrence or cancer related death | 2 (25.00%) | 4 (19.05%) | 5 (41.67%) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Arash Velayati
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Andrea Pretta
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Meng Wang
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Alessandro Audisio